The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in ...

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...

The study demonstrated improvements in memory and cognitive function for patients ... “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing ...

Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...

Nexalin's DIFS treatment improved memory and cognition in Alzheimer's ... “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing treatments by ...

Sustained drug abuse can lead to persistent memory loss and cognitive decline. Neurobiologists at the University of California San Diego have discovered a brain mechanism responsible for these ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...

NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...